RSS

PhoreMost

PhoreMost, UK-based biopharmaceutical company, has signed a collaborative agreement with Plexxikon, the small molecule structure-guided R&D centre of Daiichi Sankyo, for the identification of novel drug targets. more

News

UK based fund manager, Sixth Element Capital, has announced a £3 million investment in a spin out company from PhoreMost — NeoPhore. more

News

Biopharmaceutical company PhoreMost has entered into a research collaboration with the laboratory of Professor David Rubinsztein at the University of Cambridge. more

News

PhoreMost has been selected to receive a funding award of £1.4M from Innovate UK to develop its lead oncology programme targeting mutant KRAS cancers. more

News